SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?


To: donpat who wrote (10487)6/14/2018 12:10:36 PM
From: donpat  Respond to of 12873
 
GLAXO - What we are working on

Across our three businesses, our focus on innovation is driving a broad pipeline – from the development of everyday healthcare products to life-saving medicines and vaccines.

Pharmaceuticals

Our Pharmaceuticals R&D organisation is focused on research across four therapy areas – two core areas where we already have strong leadership developing new medicines: Respiratory and HIV/infectious diseases; and two potential areas where we have ongoing development programmes: Oncology and immuno-inflammation.

We also invest significantly in broader early discovery research, incubating areas of science outside our four core therapy areas where we think there is the potential to develop transformational medicines. This currently includes research into neuroscience and global health.

gsk.com

In this stock playing business one must anticipate and predict!!



To: donpat who wrote (10487)6/14/2018 8:23:26 PM
From: HardToFind  Read Replies (1) | Respond to of 12873
 
They've [Glaxo has] just gotta have NNVC in their sights.
I just don't think NNVC has finished making the business case for their product(s):
  1. Can we make them in commercial quantities, and how much will it cost to make them?
  2. Can we show safety & efficacy in humans, and then get drugs through FDA approval?
In my opinion, nobody at big pharma is going to reach for his or her "buyout" wallet until NNVC can answer those two questions to his or her satisfaction...and they cannot yet do that.